Product Details - EQUILIS RESEQUIN

AVAILABLE THROUGH VETS ONLY

INDICATIONS

Equilis® Resequin is indicated for the active immunization of healthy horses and ponies against respiratory diseases caused by equine herpesvirus type 1, equine herpesvirus type 4 and equine influenza virus.

COMPOSITION
Equilis® Resequin contains the following viruses:
Inactivated EHV1, Strain RAC-H at least 107.8TCID50*
Inactivated EHV4, Strain 2252 at least 106.5TCID50*
Inactivated equine influenza virus-antigens of the strains
-  A/equi 1/Prague/1/56      50µg HA**
-  A/equi 2/Newmarket/1/93 (American-lineage)   20µg HA
-  A/equi 2/Newmarket/2/93 (European-lineage)   20µg HA

  * Tissue culture infective dose 50%; determined before inactivation
** Haemagglutinin

WARNINGS
Vaccinate healthy animals only.
Slight transient reactions may occur at the sight of injection.
Hypersensitivity reactions may occur.
Do not use immunosuppressive drugs 14 days before or after vaccination.
Destroy any unused vaccine by, for example, burning and dispose of all vaccine containers after vaccination (including syringes and needles).
Do not store partially used containers for future use and use the entire contents when opened.
Shake well before use.
Avoid intravenous injection.
Keep out of reach of children and uninformed persons.
Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons.  If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS
For optimum protection, ensure regular and correctly timed vaccinations of the entire herd.
Avoid transfer of non-immunised or sick horses into correctly immunised herds.
Observe aseptic conditions.  Ensure that vaccination equipment (needles, syringes, etc.) are clean and sterile prior to use.
It is good vaccination practice when handling the vaccine to avoid contact with the eyes, hands and clothing.

DIRECTIONS FOR USE
USE ONLY AS DIRECTED
Allow the vaccine to gradually reach room temperature (20-25ºC) before use.

DOSAGE AND ADMINISTRATION
2 mℓ in the neck or chest area by deep intramuscular route.

Basic immunisation :
1st vaccination from the 4th month of life.
2nd vaccination about 6 weeks (3 weeks to 3 months) after 1st vaccination.
3rd vaccination 2 months at the earliest and 6 months at the latest after 2nd vaccination.

Booster vaccination :
After intervals of 6 months.

Note:  At a risk of an unusual threat caused by an influenza-epizootic the 3rd vaccination should already be given 2-3 months after the 2nd vaccination within the frame of basic immunisation.

PREGNANT MARES
Mares should receive a booster vaccination 4 to 8 weeks prior to parturition.  Foals from fully vaccinated mares should receive their first dose of primary vaccination course at 4 months of age.

STORAGE
Store in the dark between 2ºC and 8ºC.  Do not freeze.
Avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use.
Protect from direct sunlight.
Keep the vial in the outer carton, in order to protect from light.

PRESENTATION
Syringes: 1 x 2 mℓ (1 dose)
Vials:  5 x 2 mℓ (5 doses)
1 x 10 mℓ (5 doses)

REGISTRATION HOLDER
Intervet S.A. (Pty) Ltd
Co. Reg. No. 1991/006580/07